Truist reiterates Buy on Taylor Morrison Home stock, cites valuation

Truist reiterated a Buy on Taylor Morrison Home with an $80 price target, citing a roughly 0.9x price-to-book valuation and high-teens to 27% return-on-equity potential. The stock remains volatile, with beta at 1.51 and near-term sensitivity to 10-year Treasury moves. Recent Q1 2026 results were also strong, with EPS of $1.12 vs. $0.88 expected and revenue of $1.39B vs. $1.32B consensus.

Analysis

TMHC screens as a quality-vs-price dislocation, but the real catalyst is not the near-term print — it’s the market’s eventual willingness to pay for durability in a slower-for-longer housing tape. A sub-1x book multiple on a business earning high-ROE economics usually marks either a cyclical trough or a false signal; here, the balance sheet and backlog improvement argue this is more likely the former, especially if rates stabilize rather than fall sharply. The key second-order effect is that investors continue to underwrite TMHC like a rate beta, when the better lens is mix shift plus capital efficiency.

The active-adult exposure is the cleanest margin lever in the story. Incremental mix here can expand gross margin without requiring a major volume ramp, which matters because industry-wide supply discipline means the next leg of earnings power can come from product mix before unit growth. That also creates an underappreciated competitive angle: builders with less active-adult exposure may need to chase affordability harder, compressing margins just as TMHC can defend pricing through higher-end demographics.

The main risk is that the stock’s multiple expansion stalls if the 10-year backs up again; housing equities can de-rate faster than earnings estimates move, so this is a 1–3 month rates trade first and a 6–18 month fundamentals trade second. Another reversal risk is that analysts anchor on backlog strength and ignore cancellation sensitivity if mortgage rates reaccelerate, which would hit sentiment before reported orders. The market is likely still pricing TMHC as a cyclical with limited structural upside, so the contrarian view is that earnings quality is improving faster than the valuation model is.

Key Decisions for Investors

• Go long TMHC for a 3–6 month horizon on valuation normalization; base case favors 15–25% upside if rates stabilize, with downside limited to prior multiple support unless the 10-year re-breaks higher.
• Use a call spread in TMHC rather than outright equity if you want to express the rerating view with defined risk; the setup is better for convexity than for high carry.
• Pair trade: long TMHC / short a more rate-sensitive homebuilder with weaker mix quality and less margin flexibility over the next 1–2 quarters; this isolates the active-adult and ROE premium.
• If already long, trim only into a sharp rates-driven pop; otherwise keep the position through the next rate data cycle because the catalyst path is macro-led, not quarter-led.
• Add on weakness if TMHC trades back near book value or below, since that level appears to discount a much lower steady-state ROE than the business is currently earning.